Urolog. pro Praxi, 2011; 12(1): 12-17

Practical approach to a patient with bone metastases in urological malignacies

MUDr.Milan Král, Ph.D., MUDr.Martin Hrabec, MUDr.Michal Grepl, Ph.D., doc.MUDr.Vladimír Študent, Ph.D.
Urologická klinika LF UP a FN Olomouc

Skeletal involvement is one of the most serious topics in diagnostics and therapy of metastatic urooncological malignancies. It is a complex

process affecting normal osteogenesis which has as a consequence onset of skeletal pain, anemia due to involvement of red bone

marrow by neoplastic cells and their factors. The main danger is instability of axial skeleton with increased risk of pathological fractures

and related spinal cord compression. In this review we present current diagnostical and therapeutic options in patients with skeletal

metastasis. Besides specific approaches in prevention and therapy of bone metastasis (analgotherapy, radiation therapy, therapy with

isotopes, bisphosphonates, surgery and novel drugs) also non-specific approaches play important role (vitamin D supplementation, calcium

and physical activity). The severity of skeletal changes in oncourology is cause usually due to insufficient clinical response and this

is the challenge for further clinical research in near future.

Keywords: bone metastasis, therapy, cancer, radiation, bisphosphonates.

Published: February 25, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Král M, Hrabec M, Grepl M, Študent V. Practical approach to a patient with bone metastases in urological malignacies. Urol. praxi. 2011;12(1):12-17.
Download citation

References

  1. Mundy, GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2: 584. Go to original source... Go to PubMed...
  2. Fottner A, Szalantzy M, Wirthmann L, Stähler M, Baur-Melnyk A, Jansson V, Dürr HR. Bone metastases from renal cell carcinoma: patient survival after surgical treatment. BMC Musculoskelet Disord. 2010; 11: 145. Go to original source... Go to PubMed...
  3. Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999; 20: 345. Go to original source... Go to PubMed...
  4. Fontana A, Delmas PD. Markers of bone turnover in bone metastases. Cancer. 2000; 88(12 Suppl): 2952-2960. Go to original source...
  5. Kolombo I, Kolombova J, Dvořáček J, Hanuš T, et al. Skeletální postižení v uroonkologii. Galen 2005, p. 47.
  6. Berruti A, Tucci M, Mosca A, Tarabuzzi R, Gorzegno G, Terrone C, Vana F, Lamanna G, Tampellini M, Porpiglia F, Angeli A, Scarpa RM, Dogliotti L. Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease. Br J Cancer. 2005; 93(6): 633-638. Go to original source... Go to PubMed...
  7. Noguchi M, Kikuchi H, Ishibashi M, Noda S. Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer. Br J Cancer. 2003; 88(2): 195-201. Go to original source... Go to PubMed...
  8. http://www.shef.ac.uk/FRAX/.
  9. Adler RA. Management of osteoporosis in men on androgen deprivation therapy. Maturitas. 2010 Dec 1.
  10. Adler RA, Hastings FW, Petkov VI. Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX. Osteoporos Int. 2010; 21(4): 647-653. Epub 2009 Jun 17. Go to original source... Go to PubMed...
  11. Saylor PJ, Kaufman DS, Michaelson MD, Lee RJ, Smith MR. Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol. 2010; 183(6): 2200-2205. Go to original source... Go to PubMed...
  12. Heidenreich A, Albers P, Classen J, Graefen M, Gschwend J, Kotzerke J, Krege S, Lehmann J, Rohde D, Schmidberger H, Uder M, Zeeb H. Imaging studies in metastatic urogenital cancer patients undergoing systemic therapy: recommendations of a multidisciplinary consensus meeting of the Association of Urological Oncology of the German Cancer Society. Urol Int. 2010; 85(1): 1-10. Epub 2010 Jul 26. Go to original source... Go to PubMed...
  13. Lein M, Wirth M, Miller K, Eickenberg HU, Weissbach L, Schmidt K, Haus U, Stephan C, Meissner S, Loening SA, Jung K. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression. Eur Urol. 2007; 52(5): 1381-1387. Epub 2007 Feb 20. Go to original source... Go to PubMed...
  14. Sláma O, Vorlíček J. Nádorová bolest a možnosti její léčby. Urol List 2007; 5(2): 14-20.
  15. Doležal T, Hakl M, Kozák J, et al. Medodické pokyny pro farmakoterapii nádorové bolesti - update. Bolest 2006; 9(suppl 3): 4-8.
  16. Pandit-Taskar N, Batraki M, Divgi CR. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med. 2004; 45(8): 1358-1365. Go to PubMed...
  17. Menda, Y, Bushnell, DL, Williams, RD, et al. Efficacy and safety of repeated samarium-153 lexidronam treatment in a patient with prostate cancer and metastatic bone pain. Clin Nucl Med 2000; 25: 698. Go to original source... Go to PubMed...
  18. Poršová M, Porš J, Kolombo I, Pabišta R. Současná léča kostních metastáz. Urolog. Pro Praxi, 2007; 8(6): 272-280.
  19. Dvořáček J, Babjuk M, et al. Nádory prostaty. In: Dvořáček, et al. Onkourologie. Praha: Galen a Karolinum, 2005: 381-382.
  20. Liepe K, Kotzerke J. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun 2007; 28(8): 623-630. Go to original source... Go to PubMed...
  21. Jarolím L. Problematika kostních metastáz u karcinomu prostaty. Urolog. pro Praxi, 2008; 9(3): 109-111.
  22. Lin PP, Mirza AN, Lewis VO, Cannon CP, Tu SM, Tannir NM, Yasko AW. Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am. 2007; 89(8): 1794-1801. Go to original source... Go to PubMed...
  23. McQuay HJ, Collins SL, Carroll D, Moore RA. Radiotherapy for the palliation of painful bone metastases. Cochrane Database Syst Rev. 2000; 2: CD001793. Go to original source... Go to PubMed...
  24. Saarto T, Janes R, Tenhunen M, Kouri M. Palliative radiotherapy in the treatment of skeletal metastases. Eur J Pain. 2002; 6(5): 323-330. Go to original source... Go to PubMed...
  25. ČOS ČLS JEP: Zásady cytostatické léčby maligních onkologických onemocnění (2010). http://www.linkos.cz/odbornici/info_praxe/standardy_10_08/Zaklady_lecby_COS_2010.pdf.
  26. Dearnaley DP, Mason MD, Parmer MKB, et al. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long term overall survival results from th MRC PRO4 and Pros5 randomised contolled trials. Lancet Oncol 2009; 10: 872-876. Go to original source... Go to PubMed...
  27. Vít V. Možnosti léčby kostního postižení u karcinomu prostaty. Urol List 2009; 7(4): 27-30.
  28. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458. Go to original source... Go to PubMed...
  29. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879. Go to original source... Go to PubMed...
  30. Matoušková M, Hanuš M. Bisfosfonáty v léčbě kostních metastáz v urologii. Urolog. pro Praxi, 2009; 10(5): 282-286.
  31. Mechl Z, Kostřica R. Bisfosfonáty v léčbě metastatického kostního postižení. Onkologie 2009; 3(2): 106-110.
  32. Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, Crin? L, Dirix L, Gnant M, Gralow J, Hadji P, Hortobagyi GN, Jonat W, Lipton A, Monnier A, Paterson AH, Rizzoli R, Saad F, Thürlimann B. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 2008; 19(3): 420-432. Epub 2007 Sep 28. Go to original source... Go to PubMed...
  33. Zometa, souhrn údajů o přípravku 2010.
  34. Walter C, Al-Nawas B, Grötz KA, Thomas C, Thüroff JW, Zinser V, Gamm H, Beck J, Wagner W. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol. 2008; 54(5): 1066-1072. Epub 2008 Jun 26. Go to original source... Go to PubMed...
  35. Ruggiero S, Gralow J, Marx RE, Hoff AO, Schubert MM, Huryn JM, Toth B, Damato K, Valero V. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract. 2006; 2(1): 7-14. Go to original source... Go to PubMed...
  36. Sunyecz JA. Zoledronic acid infusion for prevention and treatment of osteoporosis. Int J Womens Health. 2010; 2: 353-360. Go to original source... Go to PubMed...
  37. Neville-Webbe HL, Coleman RE. Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease. Eur J Cancer. 2010; 46(7): 1211-1222. Epub 2010 Mar 27. Go to original source... Go to PubMed...
  38. Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, Gao G, Wu L, Sohn W, Jun S. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009; 27(10): 1564-1571. Epub 2009 Feb 23. Go to original source... Go to PubMed...
  39. Lewiecki EM. Treatment of osteoporosis with denosumab. Maturitas. 2010; 66(2): 182-186. Epub 2010 Mar 16. Go to original source... Go to PubMed...
  40. Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriguez D, Hancock ML, Steiner MS. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2010; 184(4): 1316-1321. Epub 2010 Aug 17. Go to original source... Go to PubMed...




Urology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.